Precision Vascular Robotics

Corindus Vascular Robotics (CVRS)
Overview

January 2016
FORWARD LOOKING STATEMENTS

THIS PRESENTATION CONTAINS “FORWARD-LOOKING STATEMENTS” (AS SUCH TERM IS DEFINED IN SECTION 27A OF THE SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND INFORMATION RELATING TO THE COMPANY, THAT ARE BASED ON THE CURRENT BELIEFS OF, AND ASSUMPTIONS MADE BY OUR MANAGEMENT AND THE INFORMATION CURRENTLY AVAILABLE TO OUR MANAGEMENT. FORWARD-LOOKING STATEMENTS RELATE TO EXPECTATIONS CONCERNING MATTERS THAT ARE NOT HISTORICAL FACTS. WORDS SUCH AS “ANTICIPATE,” “BELIEVE,” “ESTIMATE,” “EXPECT,” “INTEND,” “PLAN,” “PREDICT,” “OPINION,” “WILL” AND SIMILAR EXPRESSIONS AND THEIR VARIANTS, ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE FORWARD-LOOKING STATEMENTS INCLUDE, BUT ARE NOT LIMITED TO STATEMENTS RELATED TO OUR EXPECTED BUSINESS, PRODUCTS, ADOPTION OF ROBOTIC MEDICAL PROCEDURES, RESULTS OF OPERATIONS, FUTURE FINANCIAL CONDITION, ABILITY TO INCREASE OUR REVENUES, FINANCING PLANS AND CAPITAL REQUIREMENTS, OR COSTS OF REVENUE, EXPENSES, POTENTIAL TAX ASSETS OR LIABILITIES, EFFECT OF RECENT ACCOUNTING PRONOUNCEMENTS, CASH FLOWS AND ABILITY TO FINANCE OPERATIONS FROM CASH FLOWS, AND SIMILAR MATTERS. THESE FORWARD-LOOKING STATEMENTS SHOULD BE CONSIDERED IN LIGHT OF VARIOUS IMPORTANT FACTORS, INCLUDING, WITHOUT LIMITATION, THE IMPACT OF GLOBAL AND REGIONAL ECONOMIC AND CREDIT MARKET CONDITIONS ON HEALTH CARE SPENDING; HEALTH CARE REFORM LEGISLATION IN THE UNITED STATES AND ITS IMPACT ON HOSPITAL SPENDING, REIMBURSEMENT AND FEES WHICH WILL BE LEVED ON CERTAIN MEDICAL DEVICE REVENUES, DECREASES IN HOSPITAL ADMISSIONS AND ACTIONS BY PAYERS TO LIMIT OR MANAGE SURGICAL PROCEDURES TIMING AND SUCCESS OF PRODUCT DEVELOPMENT AND MARKET ACCEPTANCE OF DEVELOPED PRODUCTS, PROCEDURE COUNTS; REGULATORY APPROVALS, CLEARANCES AND RESTRICTIONS; GUIDELINES AND RECOMMENDATIONS IN THE HEALTH CARE AND PATIENT COMMUNITIES, INTELLECTUAL PROPERTY POSITIONS AND LITIGATION, COMPETITION IN THE MEDICAL DEVICE INDUSTRY AND IN THE SPECIFIC MARKETS OF SURGERY IN WHICH WE OPERATE, THE INABILITY TO MEET DEMAND FOR PRODUCTS, THE RESULTS OF LEGAL PROCEEDINGS TO WHICH WE ARE OR MAY BECOME A PARTY, PRODUCT LIABILITY AND OTHER LITIGATION CLAIMS, ADVERSE PUBLICITY REGARDING OUR COMPANY AND SAFETY OF OUR PRODUCTS AND THE ADEQUACY OF TRAINING; OUR ABILITY TO EXPAND IN FOREIGN MARKETS; AND OTHER RISK FACTORS. READERS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH ARE BASED ON CURRENT EXPECTATION AND ARE SUBJECT TO RISKS, UNCERTAINTIES; AND ASSUMPTIONS THAT ARE DIFFICULT TO PREDICT, INCLUDING THOSE RISK FACTORS DESCRIBED IN THE COMPANY’S PROSPECTUS FILED IN CONJUNCTION WITH AN S-1 REGISTRATION STATEMENT ON MAY 26, 2015. OUR ACTUAL RESULTS MAY DIFFER MATERIALLY AND ADVERSELY FROM THOSE EXPRESSED IN ANY FORWARD-LOOKING STATEMENTS. WE UNDERTAKE NO OBLIGATION TO PUBLICLY UPDATE OR RELEASE ANY REVISIONS TO THESE FORWARD-LOOKING STATEMENTS EXCEPT AS REQUIRED BY LAW.
CorPath® System: Only FDA cleared robotic-assisted percutaneous coronary intervention ("PCI") system

PCI is a high volume, (~933k), US medical robotics procedure opportunity; long growth runway

Cath Lab occupational hazards concerns and awareness are growing

CorPath precision can leading to better outcomes

Growing installed base at strategic sites

Expanding sales team and building funnel across US
### Strong Leadership Team
Experience in the cardiovascular field

<table>
<thead>
<tr>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>David Handler</strong></td>
</tr>
<tr>
<td>President &amp; CEO</td>
</tr>
<tr>
<td><strong>David Long</strong></td>
</tr>
<tr>
<td>VP Finance, CFO</td>
</tr>
<tr>
<td><strong>Gary Lickovitch</strong></td>
</tr>
<tr>
<td>VP Sales &amp; Service</td>
</tr>
</tbody>
</table>
Cath Lab Procedure Innovation
CorPath® Robotic-assisted PCI

Critical unmet interventional procedure challenges
- Innovation historically focused on stents and delivery systems
- Traditional PCI not optimized to required levels of complexity, dexterity and precision

The CorPath System offers:
- **Physicians/Staff** – radiation and orthopedic safety and robotic precision
- **Patients** – potential to improve clinical outcomes
- **Hospitals** - differentiation

First Stent Procedure
1986

Procedure Unchanged
Today

CorPath Robotic PCI
Vascular Robotics Market

CorPath platform potential to expand vascular indications

Corindus IP and Technology

Coronary  Peripheral  Neuro  Structural
Corindus Market Opportunity

$4.5B FY2018 market estimate

- New System Sales annual market opportunity based on 5-year replacement cycle in 5,430 US labs and 8,150 OUS labs, at a blended average price per system of $350,000. Prices vary by procedure type and geography.
- Non-PCI procedure types are Peripheral Vascular, Neurointerventional and Structural Heart.
- Consumables annual sales based on year 2018 estimated PCI annual procedure volume of 933,000 in the US and 1,800,000 OUS, and non-PCI annual procedure volumes of 1,200,000 in the US and 1,800,000 OUS, at an average selling price of $550 per CorPath cassette.
- The annual service revenue opportunity of $474mm is based on blended average price of $35,000 per annual service contract.
- Model does not account for custom Corindus catheter devices, or OUS opportunities beyond Europe, Japan and China, which could significantly expand market opportunity.

### New Systems ($, mm)

<table>
<thead>
<tr>
<th></th>
<th>PCI</th>
<th>Non-PCI</th>
<th>US subtotal</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>$244</td>
<td>$218</td>
<td>$462</td>
</tr>
<tr>
<td>OUS</td>
<td>$256</td>
<td>$229</td>
<td>$485</td>
</tr>
</tbody>
</table>

### Consumables ($, mm)

<table>
<thead>
<tr>
<th></th>
<th>PCI</th>
<th>Non-PCI</th>
<th>US subtotal</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>$513</td>
<td>$862</td>
<td>$1,375</td>
</tr>
<tr>
<td>OUS</td>
<td>$757</td>
<td>$1,006</td>
<td>$1,763</td>
</tr>
</tbody>
</table>

### Service ($, mm)

<table>
<thead>
<tr>
<th></th>
<th>PCI</th>
<th>Non-PCI</th>
<th>US subtotal</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>$122</td>
<td>$109</td>
<td>$231</td>
</tr>
<tr>
<td>OUS</td>
<td>$128</td>
<td>$115</td>
<td>$243</td>
</tr>
</tbody>
</table>

### Total Revenue Opportunity ($, mm)

<table>
<thead>
<tr>
<th></th>
<th>US</th>
<th>OUS</th>
<th>Worldwide opportunity</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCI</td>
<td>$879</td>
<td>$1,141</td>
<td>$1,141</td>
</tr>
<tr>
<td>Non-PCI</td>
<td>$1,190</td>
<td>$1,350</td>
<td>$1,350</td>
</tr>
<tr>
<td>US subtotal</td>
<td>$2,068</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OUS subtotal</td>
<td>$2,491</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

|        | $947   | $3,138  | $474        | $4,559         |

1 Peripheral Vascular includes lower limb, carotid, renal, iliac and AAA (abdominal aortic aneurism) procedures
2 Market opportunity assessment based on market research reports and Corindus estimate
Product Overview
CorPath Robotic-Assisted PCI System
Simple to Install and Easy to Learn

CorPath Installation

• The CorPath system fits in any cath lab and is compatible with all fluoroscopy systems; Philips, GE, Siemens, Toshiba.

• No construction is required. Several electronic cables are used to connect the bedside with the cockpit for robotics and imaging. Typical installation is one day.

• The CorPath cockpit is on wheels and can be moved within the room.

Customer Training

• Initial site training is completed in approximately four hours.

• Training includes both physicians and cath lab staff.

• Often the first commercial case is performed within a few days of initial installation.
Today’s Cath Lab Challenges

Staff Safety and Health is at Risk

- The cath lab is a dangerous environment for workers
  - Radiation exposure → cancer and cataract risk
  - Ergonomic Strain → orthopedic injury and chronic pain

Procedure Outcomes Not Optimal

- Difficulty viewing angiography standing at bedside
- Inconsistent visual assessment of length and location
- Variations in manual skill limits deployment accuracy

Hospital Economics Are Inefficient

- Above factors lead to:
  - Increased stent usage
  - Costly complications
  - Restenosis/revascularization
- Highly competitive market for PCI procedures
- Increased CMS outpatient PCI reimbursement rates in 2015
Safety in a Hazardous Environment
Reduce radiation exposure, orthopedic injury and pain

- Lab ergonomics create awkward working positions
- Lead protection exacerbates stress loading – pressures up to 300 psi on discs propagating “interventional disc disease”
- High radiation exposure – increased risk of brain tumor, leukemia/lymphoma, cataracts

- Radiation shielded work station reduces exposure from head to toe
- Improved ergonomics - work from a seated position
- No need to wear lead while in cockpit - reduced stress and fatigue
- Corindus-sponsored PRECISE study demonstrated 95.2% median reduction in physician radiation exposure
Escalating Awareness of Risks
Accelerating publication frequency
Occupational Risks in the Cath Lab

Radiation and orthopedic injury

- **Brain tumors**
  - Reported brain tumors are predominately left-side amongst interventionalists\(^1\)

- **Orthopedic injuries\(^2,4\)**
  - 60% incidence of spine issues after 21 years in practice
  - 42% incidence of spine problems -
    General population average rate - 2.3%
  - 33% miss work due to orthopedic issues

- **Cataracts**
  - 50% have significant posterior subcapsular lens changes.\(^3\)

---

1. Roguin A. Radiation hazards to interventional cardiologists: A report on increased brain tumors among physicians working in the cath lab. SOLACI 2014; April 23, 2014; Buenos Aires, Argentina.
2. Gregory Dehmer et al., Occupational Hazards for Interventional Cardiologists, The Society for Cardiovascular Angiography and Interventions, 68 Catheterization and Cardiovascular Interventions 974, 975 (2006), http://www.scai.org/asset.axd?id=0151b7-86c2-46a4-940e-e2a55e71e9bc&&t=6339458650510000
Traditional PCI vs. CorPath® Robotic PCI
Enhanced procedure may improve outcomes, economics and safety

### Traditional PCI vs. CorPath® Robotic PCI

<table>
<thead>
<tr>
<th>Traditional PCI Steps</th>
<th>PCI Steps</th>
<th>CorPath Robotic PCI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Struggle to see angiography</td>
<td>Assess Anatomy</td>
<td>Close proximity ergonomic visualization</td>
</tr>
<tr>
<td>Trial &amp; error, wire spinning</td>
<td>Navigate</td>
<td>Precise ‘Point &amp; Shoot’ predictability</td>
</tr>
<tr>
<td>‘Eyeball’ estimate</td>
<td>Measure Anatomy</td>
<td>Robotic-assisted sub-mm Measurement</td>
</tr>
<tr>
<td>Manual adjustment</td>
<td>Position Stent</td>
<td>1mm precise positioning</td>
</tr>
<tr>
<td>Devices loose during inflation</td>
<td>Deploy Stent</td>
<td>Fixated devices during deployment</td>
</tr>
</tbody>
</table>

**Open Architecture System**
- Compatible with off-the-shelf guide wires, balloons and stents from Medtronic, Abbott, BSC etc.
Precision Matters in PCI

How does precision impact patients?

- Inaccurate lesion assessment
  - ~65% physicians select stent length based on visual estimation alone\(^1\)
  - 51% of physicians underestimated lesion length\(^2\)
  - Inaccurate estimate lead to sub-optimal PCI procedure and can cause LGM
- Longitudinal Geographic Miss (LGM) correlates with higher TVR
  - STLLR trial demonstrated high incidence of LGM\(^3\)
    - Published Journal American College of Cardiology;
    - 1,557 patients, 41 US hospitals; 1 year follow up
  - 47.6%* of patients had LGM stent placements
  - LGM leads to 2.3x incidence of TVR

Target Vessel Revascularization (“TVR”) = Repeat PCI or worse!
(increased patient risk and cost implications)

---

\(^1\) 65% according to an online survey, Junicon market research 2012 – 113 interventional cardiologists. Study sponsored by Corindus Inc.


*Analyzable data set included 1419 patients (required LGM and AGM data)
## PRECISE vs. Historical Data

Compares CorPath robotic vs. historical PCI procedure

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fluoro time ≤23 min</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(N=7,242 pts)</td>
<td>(N=164 pts)</td>
</tr>
<tr>
<td>Age</td>
<td>63.9 ± 11.8</td>
<td>64.1 ± 10.0</td>
</tr>
<tr>
<td>Lesion length (mm)</td>
<td>12.8 ± 6.7</td>
<td>13.4 ± 4.0</td>
</tr>
<tr>
<td>Number of Stents</td>
<td>1.20 ± 0.83</td>
<td>1.1 ± 0.34</td>
</tr>
<tr>
<td>Fluoroscopy time (min)</td>
<td>12.7 ± 5.1</td>
<td>10.6 ± 6.2</td>
</tr>
<tr>
<td>Contrast Volume (ml)</td>
<td>242 ± 100</td>
<td>144.2 ± 70</td>
</tr>
</tbody>
</table>

- **PRECISE[^2]** study showed compared to Nikolsky[^1]:
  - 9% fewer stents
  - 16% reduction in fluoro time
  - 40% less contrast used

- **PRECISE study showed 12% LGM vs. 48% in STLLR[^3]**

[^3]: Core lab assessment of Longitudinal Geographic Miss on PRECISE dataset, data on file, Corindus Inc.
Clinical Evidence – Precision Matters
Peer reviewed publication highlights

Continued Investment in Clinical Data

- Received FDA Radial indication in Q4 2015
- Post PRECISE sub-analysis
- PRECISION registry post market data collection and analysis vs. manual procedures
- Concurrent studies to prove procedure benefits of CorPath robotic precision vs. manual procedures
  - Reduced LGM
  - Measurement accuracy
  - Visualization
  - Stent utilization
  - Contrast utilization
  - Radiation exposure
Commercial Strategy
Sales Strategy
Proven PCI Sales Leadership – Team Approach

System Sales Team
- Experienced interventional sales professionals – System ‘hunters’ and account owners
- Sales process initiates with Interventional Cardiologist champion, then progresses through hospital administration
- Leveraging both capital purchase and utilization models to accelerate sales
- Focused on largest market areas

Clinical Sales Team
- Experienced interventional procedure/device sales – procedure ‘builders’
- Initial site training and program launch
- Drive procedures and cassette sales, in depth account focus. Cath lab presence.
- Continuous use and adoption by new physician and staff users

Integrated sales and clinical field team focused on interventional cardiology leadership.
Focused on Strategic Placements
Targeting high-volume, influential IC centers

Driving awareness
• We are in the early stages of our goal to change the paradigm of how PCI procedures are performed
• Engaging key opinion leaders is integral to building awareness and driving expansion of our platform

Mayo Clinic partnership is a powerful example of our progress
• Q3 2015 - installed CorPath system at the Mayo Clinic, one of the most prestigious hospitals in the country and a high volume PCI center
• Formed a joint robotic-assisted PCI research and clinical program with the Mayo Clinic to further improve patient care as well as physician and staff safety
• Physicians are already using CorPath to treat patients and we are initiating collaborative research projects

Building strategic centers of excellence across the U.S.
Intellectual Property
Continuous “Ring-fencing” all vascular robotics applications:

- 40 issued global patents
- 53 patents pending: broad application coverage
- Continuously building IP portfolio
- Pursuing the vascular space broadly

Corindus IP covers remote control of two or more co-axial devices - a requirement for PCI and many vascular procedures
Financials
**Key Financial Information**

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash, Cash Equivalents and Marketable Securities</td>
<td>$50.3 million</td>
</tr>
<tr>
<td>Debt**</td>
<td>$9.0 million</td>
</tr>
<tr>
<td>Basic Shares Outstanding</td>
<td>118,559,200</td>
</tr>
<tr>
<td>Warrants Outstanding</td>
<td>5,207,379</td>
</tr>
<tr>
<td>Stock Options Outstanding</td>
<td>8,078,961</td>
</tr>
</tbody>
</table>

* As of September 30, 2015  
** Outstanding principal balance
Summary
Corindus Growth Platform
Interventional robotics leadership

- CorPath® System: **Only FDA cleared** robotic-assisted percutaneous coronary intervention (“PCI”) system
- Cath Lab **occupational hazards concerns** and awareness are growing
- $4.5B market opportunity; long **growth** runway
- Growing CorPath **strategic installed base** for commercial foundation and regional show sites
- Sales team expansion and funnel building across US
- Building technology and clinical experience for next application growth markets
About Corindus Vascular Robotics

Corindus Vascular Robotics is a global technology leader in robotic-assisted percutaneous coronary interventions. The company’s CorPath System is the first medical device that offers interventional cardiologists PCI procedure control from an interventional cockpit.

Visit us at www.corindus.com